ArticleIranian journal of basic medical sciences2026
CD73 blockade alleviates collagen-induced arthritis by inhibiting synovial fibroblast activity.
Article in Iranian journal of basic medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Rheumatoid arthritis (RA) is a chronic autoimmune disease with progressive cartilage erosion and joint destruction. CD73 plays a critical role in regulating inflammatory responses. This study aims to investigate the effects of CD73 blockade on RA progression and explore the potential mechanism. Materials and Methods: Soluble CD73 levels were determined by enzyme-linked immunosorbent assay. Immunohistochemistry (IHC) was used to detect CD73 expression in tissues. A collagen-induced arthritis (CIA) rat model was used to evaluate the effect of CD73 inhibitors in vivo. Hematoxylin and eosin staining was used to evaluate synovial tissue inflammation. Safranin O/Fast Green staining and Micro-CT were used to evaluate cartilage erosion and bone destruction. A live cell imaging system was used to analyze cell proliferation. Cell invasion experiments were performed using Transwell chambers. Results: Our data showed that CD73 expression was significantly increased in synovial tissues and serum from RA patients. The increased CD73 expression may be attributed to the hypoxic microenvironment via the hypoxia-inducible factor pathway in synovial tissues. Using CIA rats, our data demonstrated that CD73 blockade alleviated bone destruction and synovial inflammation. CD73 blockade inhibited synovioblast proliferation, invasion, and pro-inflammatory cytokine production. Moreover, transcriptome analysis revealed that differentially expressed genes (DEGs) in synovioblasts induced by CD73 blockade were primarily enriched for inflammatory responses, neutrophil chemotaxis, and integrin-mediated signaling pathways. Conclusion: CD73 blockade alleviated RA disease progression by regulating the activity of synovial fibroblasts. CD73 blockade is a potential therapeutic approach for patients with RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.